VANCOUVER, March 17 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon" or the "Company" TSX: DDD; OTCBB: DRUG; BBSE: DRP), a leading international pharmaceutical company, today announced it has retained cQuest, a capital markets advisory affiliate of Christensen, to facilitate and execute its investor and media relations campaigns. cQuest specializes in assisting companies with market capitalizations of less than $200 million to achieve fair market valuation and strengthen brand recognition in the global financial markets and financial media. Retaining cQuest reinforces Dragon's commitment to maximizing shareholder value by improving external communications and increasing visibility within the financial community.
"We are very excited to be working with cQuest," said Ms. Maggie Deng, Dragon's Chief Operating Officer. "The Dragon management team is committed to creating value for our shareholders with best-in-class communications and has placed a great deal of effort in finding the right investor relations firm to accomplish this goal. With its extensive global investor relations expertise with small and micro-cap companies and depth of pharmaceutical industry experience, we are confident that cQuest will assist in positioning Dragon Pharmaceutical within the investor community with a more comprehensive and customized investor and media relations program, a critical step to achieving our long term goals."
About Dragon Pharmaceutical Inc.
Dragon Pharmaceutical, headquartered in Vancouver, Canada, is a leading
manufacturer and distributor of a broad line of high-quality antibiotic
products including 7-ACA, a key intermediate to produce cephalosporin
antibiotics, Clavulanic Acid, and formulated cephalosporin antibiotic
drugs. Dragon is the third largest 7-ACA producer and the first
manufacturer and market leader of Clavulanic Acid products in China. Dragon
utilizes its nationwide sales distri
|SOURCE Dragon Pharmaceutical Inc.|
Copyright©2008 PR Newswire.
All rights reserved